http://www.protalix.com/ http://finance.yahoo.com/q/ks?s=PLX http://www.form4oracle.com/company?cik=0001006281&ticker=PLX
Protalix BioTherapeutics, Inc., a development stage company, engages in developing and producing recombinant therapeutic proteins that are expressed through its plant cell system in the United States. Its principal product candidate, prGCD, is a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme-based protein for the treatment of Gaucher Disease. The company is also developing PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; and PRX-111, a human fertility hormone targeted at the infertility market. In addition, it is developing a proprietary plant-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an oral platform for delivering active recombinant proteins systematically through enteral administration through the oral administration of transgenic plant cells. Protalix BioTherapeutics has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the company's plant cell expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher Disease, as well as a licensing agreement with Icon Genetics AG to license Icon's amplification technology for utilization in the expression of its products. The company was founded in 1993 and is based in Carmiel, Israel.